Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

A Rapid Array-Based Approach to N-Glycan Profiling of Cultured Cells.

Angel PM, Saunders J, Clift CL, White-Gilbertson S, Voelkel-Johnson C, Yeh E, Mehta A, Drake RR.

J Proteome Res. 2019 Oct 4;18(10):3630-3639. doi: 10.1021/acs.jproteome.9b00303. Epub 2019 Sep 19.

PMID:
31535553
2.

Genetic and pharmacological inhibition of acid ceramidase prevents asymmetric cell division by neosis.

White-Gilbertson S, Lu P, Norris JS, Voelkel-Johnson C.

J Lipid Res. 2019 Jul;60(7):1225-1235. doi: 10.1194/jlr.M092247. Epub 2019 Apr 15.

PMID:
30988134
3.

Expression of the SNAI2 transcriptional repressor is regulated by C16-ceramide.

Lu P, White-Gilbertson S, Nganga R, Kester M, Voelkel-Johnson C.

Cancer Biol Ther. 2019;20(6):922-930. doi: 10.1080/15384047.2019.1579962. Epub 2019 Mar 5.

PMID:
30836822
4.

Receptor-interacting Ser/Thr kinase 1 (RIPK1) and myosin IIA-dependent ceramidosomes form membrane pores that mediate blebbing and necroptosis.

Nganga R, Oleinik N, Kim J, Selvam SP, De Palma R, Johnson KA, Parikh RY, Gangaraju V, Peterson Y, Dany M, Stahelin RV, Voelkel-Johnson C, Szulc ZM, Bieberich E, Ogretmen B.

J Biol Chem. 2019 Jan 11;294(2):502-519. doi: 10.1074/jbc.RA118.005865. Epub 2018 Nov 12.

PMID:
30420430
5.

Endoplasmic reticulum stress, autophagic and apoptotic cell death, and immune activation by a natural triterpenoid in human prostate cancer cells.

Johnson BM, Radwan FFY, Hossain A, Doonan BP, Hathaway-Schrader JD, God JM, Voelkel-Johnson CV, Banik NL, Reddy SV, Haque A.

J Cell Biochem. 2019 Apr;120(4):6264-6276. doi: 10.1002/jcb.27913. Epub 2018 Oct 30.

6.

Targeting Sphingosine Kinases for the Treatment of Cancer.

Lewis CS, Voelkel-Johnson C, Smith CD.

Adv Cancer Res. 2018;140:295-325. doi: 10.1016/bs.acr.2018.04.015. Epub 2018 Jun 9. Review.

7.

Interdiction of Sphingolipid Metabolism Revisited: Focus on Prostate Cancer.

Voelkel-Johnson C, Norris JS, White-Gilbertson S.

Adv Cancer Res. 2018;140:265-293. doi: 10.1016/bs.acr.2018.04.014. Epub 2018 Jun 20. Review.

8.

N-acetyl cysteine protects anti-melanoma cytotoxic T cells from exhaustion induced by rapid expansion via the downmodulation of Foxo1 in an Akt-dependent manner.

Scheffel MJ, Scurti G, Wyatt MM, Garrett-Mayer E, Paulos CM, Nishimura MI, Voelkel-Johnson C.

Cancer Immunol Immunother. 2018 Apr;67(4):691-702. doi: 10.1007/s00262-018-2120-5. Epub 2018 Feb 2.

9.

Ceramide Synthase 6 Deficiency Enhances Inflammation in the DSS model of Colitis.

Helke K, Angel P, Lu P, Garrett-Mayer E, Ogretmen B, Drake R, Voelkel-Johnson C.

Sci Rep. 2018 Jan 26;8(1):1627. doi: 10.1038/s41598-018-20102-z.

10.

Adoptive Transfer of Ceramide Synthase 6 Deficient Splenocytes Reduces the Development of Colitis.

Scheffel MJ, Helke K, Lu P, Bowers JS, Ogretmen B, Garrett-Mayer E, Paulos CM, Voelkel-Johnson C.

Sci Rep. 2017 Nov 14;7(1):15552. doi: 10.1038/s41598-017-15791-x.

11.

Therapeutic implications of bioactive sphingolipids: A focus on colorectal cancer.

Camp ER, Patterson LD, Kester M, Voelkel-Johnson C.

Cancer Biol Ther. 2017 Sep 2;18(9):640-650. doi: 10.1080/15384047.2017.1345396. Epub 2017 Jul 7. Review.

12.

Vitamin D Modulation of TRAIL Expression in Human Milk and Mammary Epithelial Cells.

Sambandam Y, Reddy SV, Mulligan JL, Voelkel-Johnson C, Wagner CL.

Sci Rep. 2017 Jun 28;7(1):4362. doi: 10.1038/s41598-017-04521-y.

13.

Efficacy of Adoptive T-cell Therapy Is Improved by Treatment with the Antioxidant N-Acetyl Cysteine, Which Limits Activation-Induced T-cell Death.

Scheffel MJ, Scurti G, Simms P, Garrett-Mayer E, Mehrotra S, Nishimura MI, Voelkel-Johnson C.

Cancer Res. 2016 Oct 15;76(20):6006-6016.

14.

Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640.

Lewis CS, Voelkel-Johnson C, Smith CD.

Oncotarget. 2016 Sep 13;7(37):60181-60192. doi: 10.18632/oncotarget.11112.

15.

Sex differences in the MB49 syngeneic, murine model of bladder cancer.

White-Gilbertson S, Davis M, Voelkel-Johnson C, Kasman LM.

Bladder (San Franc). 2016;3(1). pii: e22. Epub 2016 Feb 26.

16.

The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo.

Venant H, Rahmaniyan M, Jones EE, Lu P, Lilly MB, Garrett-Mayer E, Drake RR, Kraveka JM, Smith CD, Voelkel-Johnson C.

Mol Cancer Ther. 2015 Dec;14(12):2744-52. doi: 10.1158/1535-7163.MCT-15-0279. Epub 2015 Oct 22.

17.

Expression of Ceramide Synthase 6 Transcriptionally Activates Acid Ceramidase in a c-Jun N-terminal Kinase (JNK)-dependent Manner.

Tirodkar TS, Lu P, Bai A, Scheffel MJ, Gencer S, Garrett-Mayer E, Bielawska A, Ogretmen B, Voelkel-Johnson C.

J Biol Chem. 2015 May 22;290(21):13157-67. doi: 10.1074/jbc.M114.631325. Epub 2015 Apr 3.

18.

Critical determinants of mitochondria-associated neutral sphingomyelinase (MA-nSMase) for mitochondrial localization.

Rajagopalan V, Canals D, Luberto C, Snider J, Voelkel-Johnson C, Obeid LM, Hannun YA.

Biochim Biophys Acta. 2015 Apr;1850(4):628-39. doi: 10.1016/j.bbagen.2014.11.019. Epub 2014 Dec 4.

19.

STAT-6 mediates TRAIL induced RANK ligand expression in stromal/preosteoblast cells.

Sundaram K, Sambandam Y, Balasubramanian S, Pillai B, Voelkel-Johnson C, Ries WL, Reddy SV.

Bone. 2015 Feb;71:137-44. doi: 10.1016/j.bone.2014.10.016. Epub 2014 Oct 30.

PMID:
25445452
20.

Promoting thiol expression increases the durability of antitumor T-cell functions.

Kesarwani P, Al-Khami AA, Scurti G, Thyagarajan K, Kaur N, Husain S, Fang Q, Naga OS, Simms P, Beeson G, Voelkel-Johnson C, Garrett-Mayer E, Beeson CC, Nishimura MI, Mehrotra S.

Cancer Res. 2014 Nov 1;74(21):6036-6047. doi: 10.1158/0008-5472.CAN-14-1084. Epub 2014 Aug 27.

21.

Sphingosine kinase-2 maintains viral latency and survival for KSHV-infected endothelial cells.

Dai L, Plaisance-Bonstaff K, Voelkel-Johnson C, Smith CD, Ogretmen B, Qin Z, Parsons C.

PLoS One. 2014 Jul 10;9(7):e102314. doi: 10.1371/journal.pone.0102314. eCollection 2014.

22.

Polymer-enhanced delivery increases adenoviral gene expression in an orthotopic model of bladder cancer.

Gosnell H, Kasman LM, Potta T, Vu L, Garrett-Mayer E, Rege K, Voelkel-Johnson C.

J Control Release. 2014 Feb 28;176:35-43. doi: 10.1016/j.jconrel.2013.12.012. Epub 2013 Dec 24.

23.

An orthotopic bladder cancer model for gene delivery studies.

Kasman L, Voelkel-Johnson C.

J Vis Exp. 2013 Dec 1;(82):50181. doi: 10.3791/50181.

24.

Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma.

Qin Z, Dai L, Trillo-Tinoco J, Senkal C, Wang W, Reske T, Bonstaff K, Del Valle L, Rodriguez P, Flemington E, Voelkel-Johnson C, Smith CD, Ogretmen B, Parsons C.

Mol Cancer Ther. 2014 Jan;13(1):154-64. doi: 10.1158/1535-7163.MCT-13-0466. Epub 2013 Oct 18.

25.

Inner ear supporting cells protect hair cells by secreting HSP70.

May LA, Kramarenko II, Brandon CS, Voelkel-Johnson C, Roy S, Truong K, Francis SP, Monzack EL, Lee FS, Cunningham LL.

J Clin Invest. 2013 Aug;123(8):3577-87. doi: 10.1172/JCI68480. Epub 2013 Jul 25.

26.

Sphingolipids in apoptosis.

Tirodkar TS, Voelkel-Johnson C.

Exp Oncol. 2012 Oct;34(3):231-42. Review.

PMID:
23070008
27.

Dissection of adult mouse utricle and adenovirus-mediated supporting-cell infection.

Brandon CS, Voelkel-Johnson C, May LA, Cunningham LL.

J Vis Exp. 2012 Mar 28;(61). pii: 3734. doi: 10.3791/3734.

28.
29.

TRAIL-mediated signaling in prostate, bladder and renal cancer.

Voelkel-Johnson C.

Nat Rev Urol. 2011 Jun 14;8(8):417-27. doi: 10.1038/nrurol.2011.81. Review.

PMID:
21670755
30.

T cells expanded in presence of IL-15 exhibit increased antioxidant capacity and innate effector molecules.

Kaur N, Naga OS, Norell H, Al-Khami AA, Scheffel MJ, Chakraborty NG, Voelkel-Johnson C, Mukherji B, Mehrotra S.

Cytokine. 2011 Aug;55(2):307-17. doi: 10.1016/j.cyto.2011.04.014. Epub 2011 May 23.

31.

Adenoviral infectivity of exfoliated viable cells in urine: implications for the detection of bladder cancer.

Murali A, Kasman L, Voelkel-Johnson C.

BMC Cancer. 2011 May 12;11:168. doi: 10.1186/1471-2407-11-168.

32.

Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells.

Park MA, Reinehr R, Häussinger D, Voelkel-Johnson C, Ogretmen B, Yacoub A, Grant S, Dent P.

Mol Cancer Ther. 2010 Aug;9(8):2220-31. doi: 10.1158/1535-7163.MCT-10-0274. Epub 2010 Aug 3.

33.

Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway.

Park MA, Mitchell C, Zhang G, Yacoub A, Allegood J, Häussinger D, Reinehr R, Larner A, Spiegel S, Fisher PB, Voelkel-Johnson C, Ogretmen B, Grant S, Dent P.

Cancer Res. 2010 Aug 1;70(15):6313-24. doi: 10.1158/0008-5472.CAN-10-0999. Epub 2010 Jul 14.

34.

17-allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species.

Walker T, Mitchell C, Park MA, Yacoub A, Rahmani M, Häussinger D, Reinehr R, Voelkel-Johnson C, Fisher PB, Grant S, Dent P.

Mol Cancer Ther. 2010 May;9(5):1378-95. doi: 10.1158/1535-7163.MCT-09-1131. Epub 2010 May 4.

35.

Polymer-enhanced adenoviral transduction of CAR-negative bladder cancer cells.

Kasman LM, Barua S, Lu P, Rege K, Voelkel-Johnson C.

Mol Pharm. 2009 Sep-Oct;6(5):1612-9. doi: 10.1021/mp9000958.

36.

Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-1(27-35)-reactive T cells from activation-induced cell death.

Norell H, Martins da Palma T, Lesher A, Kaur N, Mehrotra M, Naga OS, Spivey N, Olafimihan S, Chakraborty NG, Voelkel-Johnson C, Nishimura MI, Mukherji B, Mehrotra S.

Cancer Res. 2009 Aug 1;69(15):6282-9. doi: 10.1158/0008-5472.CAN-09-1176. Epub 2009 Jul 28.

37.

Oxidative stress sensitizes bladder cancer cells to TRAIL mediated apoptosis by down-regulating anti-apoptotic proteins.

White-Gilbertson SJ, Kasman L, McKillop J, Tirodkar T, Lu P, Voelkel-Johnson C.

J Urol. 2009 Sep;182(3):1178-85. doi: 10.1016/j.juro.2009.05.005. Epub 2009 Jul 21.

38.

Oxidative stress and lymphocyte persistence: implications in immunotherapy.

Mehrotra S, Mougiakakos D, Johansson CC, Voelkel-Johnson C, Kiessling R.

Adv Cancer Res. 2009;102:197-227. doi: 10.1016/S0065-230X(09)02006-5. Review.

PMID:
19595310
39.

The role of protein synthesis in cell cycling and cancer.

White-Gilbertson S, Kurtz DT, Voelkel-Johnson C.

Mol Oncol. 2009 Dec;3(5-6):402-8. doi: 10.1016/j.molonc.2009.05.003. Epub 2009 Jun 11. Review.

40.

Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms.

Walker T, Mitchell C, Park MA, Yacoub A, Graf M, Rahmani M, Houghton PJ, Voelkel-Johnson C, Grant S, Dent P.

Mol Pharmacol. 2009 Aug;76(2):342-55. doi: 10.1124/mol.109.056523. Epub 2009 May 29.

41.

MDA-7/IL-24-induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK-dependent mechanism.

Park MA, Walker T, Martin AP, Allegood J, Vozhilla N, Emdad L, Sarkar D, Rahmani M, Graf M, Yacoub A, Koumenis C, Spiegel S, Curiel DT, Voelkel-Johnson C, Grant S, Fisher PB, Dent P.

Mol Cancer Ther. 2009 May;8(5):1280-91. doi: 10.1158/1535-7163.MCT-09-0073. Epub 2009 May 5.

42.

Ceramide synthase 6 modulates TRAIL sensitivity and nuclear translocation of active caspase-3 in colon cancer cells.

White-Gilbertson S, Mullen T, Senkal C, Lu P, Ogretmen B, Obeid L, Voelkel-Johnson C.

Oncogene. 2009 Feb 26;28(8):1132-41. doi: 10.1038/onc.2008.468. Epub 2009 Jan 12.

43.

Combination therapy with TRAIL: Recent developments and potential pitfalls.

Voelkel-Johnson C.

Cancer Biol Ther. 2009 Jan;8(1):81-3. Epub 2009 Jan 29. No abstract available.

PMID:
19127121
44.

Transformation, translation and TRAIL: an unexpected intersection.

White-Gilbertson S, Rubinchik S, Voelkel-Johnson C.

Cytokine Growth Factor Rev. 2008 Apr;19(2):167-72. doi: 10.1016/j.cytogfr.2008.01.007. Review.

45.

Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2.

White SJ, Kasman LM, Kelly MM, Lu P, Spruill L, McDermott PJ, Voelkel-Johnson C.

Free Radic Biol Med. 2007 Nov 1;43(9):1313-21. Epub 2007 Jul 3.

46.

Illuminating TRAIL gene therapy.

White SJ, Voelkel-Johnson C.

Cancer Biol Ther. 2006 Nov;5(11):1521-2. Epub 2006 Nov 11. No abstract available.

PMID:
17204862
47.
48.

Targeting the short form of cFLIP by RNA interference is sufficient to enhance TRAIL sensitivity in PC3 prostate carcinoma cells.

White SJ, Lu P, Keller GM, Voelkel-Johnson C.

Cancer Biol Ther. 2006 Dec;5(12):1618-23. Epub 2006 Dec 5.

PMID:
17106251
49.

Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report.

Norris JS, Bielawska A, Day T, El-Zawahri A, ElOjeimy S, Hannun Y, Holman D, Hyer M, Landon C, Lowe S, Dong JY, McKillop J, Norris K, Obeid L, Rubinchik S, Tavassoli M, Tomlinson S, Voelkel-Johnson C, Liu X.

Cancer Gene Ther. 2006 Dec;13(12):1045-51. Epub 2006 Jun 9. Review.

PMID:
16763610

Supplemental Content

Loading ...
Support Center